Jerome Tavernier1, Philippe Fagnoni2, Pascal Chabrot3, Boris Guiu4, Lucie Vadot5, Serge Aho6, Louis Boyer3, Armand Abergel7, Patrick Hillon8, Valerie Sautou9, Mathieu Boulin10. 1. Department of Pharmacy, University Hospital, Clermont-Ferrand, France. 2. Department of Pharmacy, University Hospital, Dijon, France EA 4184, Burgundy University, Dijon, France. 3. Department of Interventional Radiology, University Hospital, Clermont-Ferrand, France ISIT UMR CNRS 6284, Auvergne University, Clermont-Ferrand, France. 4. Department of Interventional Radiology, University Hospital, Dijon, France INSERM U866, Burgundy University, Dijon, France. 5. Department of Pharmacy, University Hospital, Dijon, France. 6. Department of Hospital Hygiene and Epidemiology, University Hospital, Dijon, France. 7. ISIT UMR CNRS 6284, Auvergne University, Clermont-Ferrand, France Department of Hepato-Gastroenterology, University Hospital, Clermont-Ferrand, France. 8. EA 4184, Burgundy University, Dijon, France Department of Hepato-Gastroenterology, University Hospital, Dijon, France. 9. Department of Pharmacy, University Hospital, Clermont-Ferrand, France EA 4676 C-BIOSENSS, Auvergne University, Clermont-Ferrand, France. 10. Department of Pharmacy, University Hospital, Dijon, France EA 4184, Burgundy University, Dijon, France mathieuboulin@yahoo.fr.
Abstract
AIM: This retrospective study aimed to compare the efficacy of and tolerance to two center-related conventional transarterial chemoembolization (TACE) strategies in the management of unresectable hepatocellular carcinoma (HCC). PATIENTS AND METHODS: All HCC patients in whom TACE was initiated in the two centers from June 2008 to July 2011 were included. The TACE strategy performed in center 1 was "on demand" with selective injections of idarubicin, whereas the TACE strategy in center 2 was based "on scheduled" non-selective injections of epirubicin. Toxicity was evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0. RESULTS: One hundred and fifty HCC patients were included. Median time to treatment failure was significantly higher in center 1, 13.1 months vs. 7.9 months in center 2 (hazard ratio, 2.32; p<10-3 in multivariate analysis). Median overall survival was 21.1 months in center 1 vs. 18.4 months in center 2 (p=NS). The proportion of grade ≥ 3 adverse events and mean hospitalisation duration for the overall TACE treatment were significantly greater in center 2 than in center 1: 56% vs. 32% (p<0.01) and 14.2 ± 7.2 days vs. 10.3 ± 7.0 days (p<0.01), respectively. CONCLUSION: Our results failed to show any significant survival differences between two center-related TACE strategies but showed a significantly smaller proportion of grade ≥ 3 adverse events and shorter hospitalisation for the overall treatment when the "on-demand" strategy was used. Copyright
AIM: This retrospective study aimed to compare the efficacy of and tolerance to two center-related conventional transarterial chemoembolization (TACE) strategies in the management of unresectable hepatocellular carcinoma (HCC). PATIENTS AND METHODS: All HCC patients in whom TACE was initiated in the two centers from June 2008 to July 2011 were included. The TACE strategy performed in center 1 was "on demand" with selective injections of idarubicin, whereas the TACE strategy in center 2 was based "on scheduled" non-selective injections of epirubicin. Toxicity was evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0. RESULTS: One hundred and fifty HCC patients were included. Median time to treatment failure was significantly higher in center 1, 13.1 months vs. 7.9 months in center 2 (hazard ratio, 2.32; p<10-3 in multivariate analysis). Median overall survival was 21.1 months in center 1 vs. 18.4 months in center 2 (p=NS). The proportion of grade ≥ 3 adverse events and mean hospitalisation duration for the overall TACE treatment were significantly greater in center 2 than in center 1: 56% vs. 32% (p<0.01) and 14.2 ± 7.2 days vs. 10.3 ± 7.0 days (p<0.01), respectively. CONCLUSION: Our results failed to show any significant survival differences between two center-related TACE strategies but showed a significantly smaller proportion of grade ≥ 3 adverse events and shorter hospitalisation for the overall treatment when the "on-demand" strategy was used. Copyright
Authors: Pierleone Lucatelli; Gianluca De Rubeis; Fabrizio Basilico; Luca Ginanni Corradini; Mario Corona; Mario Bezzi; Carlo Catalano Journal: Radiol Med Date: 2019-08-31 Impact factor: 3.469